Palazestrant, a novel oral Complete Estrogen Receptor Antagonist (CERAN) and Selective Estrogen Receptor Degrader (SERD), in patients with ER+/HER2− advanced or metastatic breast cancer: phase 1/2 study results

Abstract Background Endocrine resistance is a major challenge in treating patients with ER+ /HER2− metastatic breast cancer (MBC) necessitating a switch from endocrine therapy to more toxic therapies. Mutations in ESR1 constitute a key mechanism of resistance to endocrine therapy in ER+ /HER2− BC. T...

Descripció completa

Dades bibliogràfiques

Autors principals:	Erika P. Hamilton, Manish R. Patel, Virginia F. Borges, Jane L. Meisel, Meena Okera, Carlos A. Alemany, Timothy J. Pluard, Robert Wesolowski, Dhanusha Sabanathan, Kathy D. Miller, Alison K. Conlin, Nicole McCarthy, Morena Shaw, Margaret Tonda, Mark Shilkrut, Nancy U. Lin
Format:	Artigo
Idioma:	Inglês
Publicat:	BMC 2025-07-01
Col·lecció:	Breast Cancer Research
Matèries:	Complete estrogen receptor antagonist Selective estrogen receptor degrader Estrogen receptor-positive human epidermal growth factor receptor 2-negative metastatic breast cancer Endocrine therapy Palazestrant Estrogen receptor mutation
Accés en línia:	https://doi.org/10.1186/s13058-025-02049-y
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!